COPD

Two tablets displaying screenshots of the Bridging Specialties®: Timely Diagnosis and Treatment for COPD modules

Bridging Specialties®: Timely Diagnosis and Treatment for COPD

CHEST is developing tools and resources for pulmonologists, primary care physicians, and advanced practice providers to help improve the time to diagnosis and treatment for COPD. Learn how to administer appropriate diagnostic tests, determine the severity of disease, and proceed with next steps in the treatment and management of COPD.

LEARN MORE »

Supported by Regeneron Pharmaceuticals, Inc, and Sanofi

Two tablets displaying screenshots of the Bridging Specialties®: Timely Diagnosis and Treatment for COPD modules

Join the Airways Disorders Network

CHEST Networks are specialty-focused communities that provide forums for leadership, education, and advocacy. The Airways Disorders Network educates clinicians about airways disorders, including asthma, COPD, emphysema, bronchiectasis, chronic bronchitis, pediatric medicine, and diseases of large and small airways.

LEARN MORE »

COPD news and notes

Follow the latest COPD news

ASTHMA AND COPD SECTION

Expanding Treatments for COPD Management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.

BRONCHIECTASIS SECTION

Strengthening More Than Just Airways
Emerging research reveals that nutrition and exercise are two powerful yet underutilized tools in managing bronchiectasis.

PEDIATRIC CHEST MEDICINE SECTION

Advancements in Pediatric Airway Evaluation
Pediatric airway anatomy evaluation continues to evolve with the development of newer technologies such as dynamic volumetric computed tomography.

PULMONARY PHYSIOLOGY AND REHABILITATION SECTION

GOLDen Handcuffs: Beyond Spirometry in COPD
When it comes to diagnosing COPD, clinicians must look beyond spirometry and physiology to see a patient fully.

PULMONARY PERSPECTIVES®

A Sticky Road: Mucus Pathology in COPD
Targeting mucus pathology could provide a novel approach to addressing the underlying mechanisms contributing to airway obstruction.

CHEST PHYSICIAN®

MATINEE Shows Positive Results for Mepolizumab in COPD
Clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.

Build your COPD expertise

CHEST SEEK® Education

Written and peer reviewed by renowned experts in the critical care, pulmonary, and sleep medicine fields, the online CHEST SEEK Library and print publications include case-based questions and detailed rationales to stimulate and challenge your clinical thought process; help you prepare for certification or recertification exams; and allow you to obtain CME credit, MOC points, and CE hours.


CHEST SEEK LIBRARY

Access hundreds of critical care, pulmonary, and sleep medicine questions.

PURCHASE NOW »

Join the community

If you’re not already a CHEST member, become one today for access to additional resources, discounts on educational activities, and networking opportunities.

JOIN NOW »